Characterisation of Cytotoxicity-Related Receptors on γδ T Cells in Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is a haematological malignancy primarily affecting older adults, characterised by the proliferation of functionally impaired B lymphocytes with abnormal expression of CD5, a typical T cell marker. The current study investigates the expression of cytotoxicity-relat...

Full description

Saved in:
Bibliographic Details
Main Authors: Michał Zarobkiewicz, Natalia Lehman, Izabela Morawska-Michalska, Adam Michalski, Wioleta Kowalska, Agata Szymańska, Waldemar Tomczak, Agnieszka Bojarska-Junak
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/14/6/451
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic lymphocytic leukaemia (CLL) is a haematological malignancy primarily affecting older adults, characterised by the proliferation of functionally impaired B lymphocytes with abnormal expression of CD5, a typical T cell marker. The current study investigates the expression of cytotoxicity-related receptors (CD16, CD56, CD57, CD69) and a checkpoint (LAG-3) on γδ T cells in CLL patients. Sixty-nine treatment-naive CLL patients and fourteen healthy controls were recruited. Flow cytometry analysis revealed that the CLL patients had higher expressions of CD56 and LAG-3 and lower CD16 on their γδ T cells compared to the healthy controls. Subgroup analysis showed that ZAP-70-negative patients exhibited increased CD69, while CD38-negative patients showed higher CD16 expression. Additionally, CD16 expression was inversely correlated with serum LDH levels, a marker of disease progression. Bioinformatic analysis of the LAG-3 ligand mRNA in a CLL dataset indicated higher expression of <i>HLA-DQA2</i> and <i>HLA-DRB5</i> in patients with unmutated <i>IGVH</i>. Our findings highlight the altered expression of key cytotoxicity markers on γδ T cells in CLL, suggesting their potential role in disease progression and as a therapeutic target. In particular, the use of anti-LAG-3 antibodies seems promising.
ISSN:2073-4409